文献速递细菌感染、耐药与抗菌药物

利奈唑胺与复方磺胺甲噁唑联合利福平治疗MRSA感染的成本效果比较:医疗系统视角

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective.
PubMed 文献 · Clin Microbiol Infect · 2017-02-20

该研究从医疗系统视角,基于既往临床试验的成本与效果数据,对利奈唑胺与复方磺胺甲噁唑联合利福平治疗MRSA感染进行随机成本效果分析。结果显示,联合方案平均成本€146、获得0.916 QALYs,利奈唑胺平均成本€2536、获得0.881 QALYs,联合方案在大多数情景中占优。

要点

  • 复方磺胺甲噁唑联合利福平治疗MRSA感染的成本效果优于利奈唑胺。
  • 联合方案平均成本€146、0.916 QALYs;利奈唑胺€2536、0.881 QALYs。
  • 利奈唑胺需降价95%才可能比联合方案更具成本效果。

核心结论

  • 复方磺胺甲噁唑联合利福平治疗MRSA感染比利奈唑胺更具成本效果。

研究设计与样本

  • 基于既往临床试验的成本与效果数据,并补充已发表文献数据,从医疗系统视角进行随机成本效果分析。
  • 效果以质量调整生命年(QALYs)表示,采用蒙特卡罗模拟进行敏感性分析。

主要发现

  • 复方磺胺甲噁唑联合利福平平均成本€146,获得0.916 QALYs;利奈唑胺平均成本€2536,获得0.881 QALYs。
  • 在支付意愿阈值为€0、€50 000和€200 000/QALY时,联合方案在100%、96%和85%的模型迭代中占优。
  • 利奈唑胺需在当前采购价基础上降价95%才可能比联合方案更具成本效果。

关键数值与推荐

  • 复方磺胺甲噁唑联合利福平在基础分析及大多数替代情景中均占优,包括不同MRSA感染类型和潜在毒性劣势。

临床怎么用

  • 在医疗系统视角下,可优先考虑复方磺胺甲噁唑联合利福平治疗MRSA感染以提升成本效果。

局限性

  • 成本效果数据主要源于既往单一临床试验,并补充文献数据,可能存在参数不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection. METHODS: We used cost and effectiveness data from a previously conducted clinical trial, complementing with other data from published literature, to compare the two regimens from a healthcare system perspective. Effectiveness was expressed in terms of quality-adjusted life-years (QALYs). Several sensitivity analyses were performed using Monte Carlo simulation, to measure the effect of potential parameter changes on the base-case model results, including potential differences related to type of infection and drug toxicity. RESULTS: Treatment of MRSA infection with trimethoprim-sulfamethoxazole plus rifampicin and linezolid were found to cost on average €146 and €2536, and lead to a gain of 0.916 and 0.881 QALYs, respectively. Treatment with trimethoprim-sulfamethoxazole plus rifampicin was found to be more cost-effective than linezolid in the base case and remained dominant over linezolid in most alternative scenarios, including different types of MRSA infection and potential disadvantages in terms of toxicity. With a willingness-to-pay threshold of €0, €50 000 and €200 000 per QALY gained, trimethoprim-sulfamethoxazole plus rifampicin was dominant in 100%, 96% and 85% of model iterations. A 95% discount on the current purchasing price of linezolid would be needed when it goes off-patent for it to represent better value for money compared with trimethoprim-sulfamethoxazole plus rifampicin. CONCLUSIONS: Combined treatment of trimethoprim-sulfamethoxazole plus rifampicin is more cost-effective than linezolid in the treatment of MRSA infection.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. von Dach E, Morel CM, Murthy A, et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. Clin Microbiol Infect. 2017. PMID: 28232163. doi:10.1016/j.cmi.2017.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。